EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise
Executive Summary
Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.
You may also be interested in...
CMS Proposes Coverage Policy For Transcatheter Edge-to-Edge Mitral Valve Repair
In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.
Abbott Stays Ahead Of Edwards In Transcatheter Mitral Valve Race With Tendyne CE Mark
Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.
Q3 Earnings Spotlight: Abiomed Shines Among Cardiology Device-Makers
Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.